Showing results (261-270 of 298) with videos related to

Sort By:
Pageof 30
British Journal of Cancer|December 19, 2023
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancerBolin Chen, Wenxiu Yao, Xingya Li, et al.
Nature Communications|October 20, 2021
PHF3 regulates neuronal gene expression through the Pol II CTD reader domain SPOCLisa-Marie Appel, Vedran Franke, Melania Bruno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2024
Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG StudyJin-Ji Yang, Yan Zhang, Lin Wu, et al.
Lung Cancer (Amsterdam, Netherlands)|November 28, 2019
Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective studyJia-Tao Zhang, Ye Li, Li-Xu Yan, et al.
Frontiers in Immunology|November 28, 2022
CD8<sup>+</sup> T cell/cancer-associated fibroblast ratio stratifies prognostic and predictive responses to immunotherapy across multiple cancer typesXinlong Zheng, Kan Jiang, Weijin Xiao, et al.
Nature Biotechnology|May 8, 2018
Multiplexed precision genome editing with trackable genomic barcodes in yeastKevin R Roy, Justin D Smith, Sibylle C Vonesch, et al.
Cell Reports|May 31, 2025
Cell-death pathways and tau-associated neuronal vulnerability in Alzheimer's diseaseGen Lin, Sarah E Chancellor, Taekyung Kwon, et al.
Frontiers in Immunology|August 29, 2022
Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinomaChao Li, Xiaobin Zheng, Pansong Li, et al.
Medcomm|March 11, 2024
A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response scoreXinlong Zheng, Tao Lu, Shiwen Wu, et al.
Future Oncology (London, England)|October 30, 2025
Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational studyHua Zhong, Shunjun Jiang, Wenxiu Yao, et al.
Pageof 30